The in vitro bactericidal interactions of three new extended-spectrum cephalosporins (ceftriaxone, ceftizoxime, or ceftazidime) in combination with gentamicin or amikacin were compared against 40 recent nosocomial bloodstream Enterobacteriaceae isolates by the timed-kill curve technique. All of the study strains were cephalothin resistant, and 56% were resistant to cefamandole. Combinations of aminoglycosides plus ceftriaxone or ceftizoxime exhibited an enhanced bactericidal effect with the highest frequency (-85 to 90%), whereas gentamicin-ceftazidime combinations demonstrated the lowest frequency (for 60% of assays, P < 0.0005 against the nonceftazidime regimens). The enhanced bactericidal effects occurred within readily achievable drug levels in serum for all of the single antibiotic constituents. No bactericidal antagonism was observed. There was no discernible relationship between the relative in vitro susceptibilities of the 40 study isolates to ceftazidime and the potential for gentamicin-ceftazidime combinations to demonstrate enhanced bactericidal activity. In 14 of the 40 study strains (35%) all six drug combinations tested demonstrated an enhanced bactericidal effect. In nearly 50% of bactericidal interactions which resulted in enhanced bactericidal effect at 24 h, such enhanced killing was clearly demonstrable by 4 h of incubation. These results delineate a frequent and rapid enhancement of in vitro bactericidal activity between three new extended-spectra cephalosporins and aminoglycosides against nosocomial members of the family Enterobacteriaceae.
Members of the family Enterobacteriaceae have become frequent etiological agents in clinical syndromes in which bactericidal antibiotics are felt to be important. This includes sepsis in neutropenic cancer patients and neonatal and nosocomial meningitis (4, 10, 14, 19, 20) . Acquired drug resistance among recent nosocomial Enterobacteriaceae isolates to earlier "generation" P-lactams and older aminoglycosides has been increasingly prevalent (16) . This has prompted us to examine several newly developed agents against these pathogens. In this regard, we investigated the potential of three new extended-spectrum f3-lactam agents (ceftriaxone, ceftizoxime, and ceftazidime) to enhance the in vitro killing of recent Enterobacteriaceae isolates in combination with selected aminoglycosides.
(This investigation was presented in part at the 23rd Interscience Conference on Antimicrobial Agents and Chemotherapy [A. S. Bayer, R. Eisenstadt, and J. 0. Morrison, Program Abstr. Intersci. Conf. Antimicrob. Agents Chemother. 23rd, Las Vegas, Nev., abstr. no. 35, 1983] .) Bacterial strains. The organisms for study were 40 nosocomial bloodstream Enterobacteriaceae isolates from the Clinical Microbiology Laboratory of Harbor-UCLA Medical Center during the years 1981-1983. There were 22 Enterobacter isolates, including 16 Enterobacter cloacae; there were 12 Serratia marcescens isolates. The remaining six isolates were as follows: Klebsiella pneumoniae (two), Escherichia coli (two), Citrobacter diversus (one), and Hafnia sp. (one). All isolates were identified and speciated by standard criteria (3). * Corresponding author.
Antibiotics. For testing of MICs and MBCs, the following antibiotics were utilized: ceftriaxone (Hoffman-LaRoche, Inc., Nutley, N.J.), ceftazidime (Glaxo Research, Durham, N.C.), ceftizoxime (Smith Kline & French Laboratories, Philadelphia, Pa.), gentamicin (Schering Laboratories, Kenilworth, N.J.), and amikacin (Bristol Laboratories, Syracuse, N.Y.). All antibiotics were prepared in a final concentration of 10,000 ,ug/ml in sterile distilled water and stored at -70°C. After thawing, appropriate dilutions of these antibiotics in unsupplemented Mueller-Hinton broth (MHB; BBL Microbiology Systems, Cockeysville, Md.) were prepared on the day of susceptibility testing. Unsupplemented MHB has a maximal concentration of 0.5 mg/100 ml of magnesium and 3.1 mg/100 ml of calcium.
Antimicrobial susceptibility testing. Determination of MIC and MBC. The broth macrodilution method as described by Ericsson and Sherris (6) was used to determine MIC and MJ3C. A logarithmic-phase inoculum (in MHB) of each isolate to be tested was appropriately diluted and added to serial twofold dilutions of the antibiotic (1 ml + 1 ml) to provide -5 x 105 CFU/ml in each tube. The inoculum size was confirmed by formal dilution pour plate quantitations.
The tubes were then incubated at 37°C for 18 containing only MHB and study organisms was included as a positive growth control.
For ceftriaxone, ceftizoxime, and ceftazidime, the range of concentrations in antibiotic-containing tubes was 0.062 to 64 jig/ml; for gentamicin, the range was 0.25 tp 16 ,ug/ml; and for amikacin, the range was 0.5 to 32 ,ug/ml. the drug concentrations were chosen to encompass readily-obtainable levels in serum after standard dose parenteral regimens (8) .
Bactericidal interaction testing. For bactericidal interaction testing, the tim'ed-kill curve technique was employed (7). The drug combinations tested were ceftriaxone, ceftizoxime, or ceftazidime plus gentamicin or amikacin. The drugs were tested singly or in combination at the previously determined MBCs or fractions thereof. In -75% of testings, utilizing each agent in a combination at its respective MBC was adequate to define the nature of the bactericidal interaction. In -'--25% of determinations, the single drugs in a combination were each tested at one-half or one-fourth the respective MBCs because of rapid killing of the isolate within 4 h of incubation by the single agents when tested at the MBC.
Antibiotic-contRiining M'HB (9.9 ml) was inoculated with a log-phase ipoculum (0.1 ml) of each isolate to be tested to achieve a final inoculpm per tube of -5 x 1Q5 CFU/ml. The tubes each contairled 3-lactam and aminoglycoside, alone or in combination. A tube with antibiotic-free MHB and bacterfal inoculum was' included in each run as a positive growth control. The tubes were incubated with gentle shaking for 24 h at 37TC. Samples (10 ,u) None of the 40 isolates was highly resistant to the inhibitory or killing action of the five study drugs.
Bactericidal interaction testing. cidal activity of ceftazidime (MBC, s8 ,ug/ml), and eight (20%) were moderately susceptible (MBC = 16 -64 ,ug/ml). Of the 32 strains with MBCs '8 ,ug/ml, 60% exhibited enhanced killing against gentamicin-ceftazidime combinations; the remaining 40% showed an indifferent interaction. Among the eight strains moderately susceptible to ceftazidime, five demonstrated enhanced killing, whereas three were indifferent to gentamicin-ceftazidime regimens. Thus, there was no apparent relationship between the relative in vitro susceptibilities of the study isolates to ceftazidime and the potential to demonstrate enhanced bactericidal activity to the drug combinations. Similar findings were noted in analyzing the two other P-lactams in this investigation.
(ii) Study organisms. To determine whether the individual genus or species affected the results of bactericidal interaction testing, we examined the two largest subgroups of strains in our study, Serratia strains (n = 12) and Enterobacter strains (n = 22). For the Enterobacter strains, there were no significant differences in frequency of enhanced bactericidal effect in comparing gentamicin versus amikacin plus P-lactam regimens (80 versus 85%, respectively; P > 0.10). Among Serratia strains, more amikacin plus P-lactam regimens exhibited an enhanced bactericidal effect than comparable gentamicin regimens (97 versus 82%; P < 0.10, > 0.05). DISCUSSION In addition to the prevalence of the Enterobacteriaceae in life-threatening syndromes requiring bactericidal antibiotics for cure (4, 9, 10, 14, (19) (20) (21) , acquired drug resistance of these strains to older P-lactams and aminoglycoside antibiotics has become a significant problem. Gentamicin resistance among recent nosocomial Enterobacteriaceae isolates ranges from -20 to 50% in certain parts of the United States and Europe, particularly involving Serratia, Enterobacter, and indole-positive Proteus species (18, 22) . Similarly, many recent Enterobacteriaceae isolates exhibit a high frequency of resistance to earlier generation cephalosporins such as cephalothin, cefazolin, and cefoxitin, with MIC90s >64 ,ug/ The present investigation demonstrated several interesting findings. (i) Approximately 75% of our 40 study isolates were very susceptible to the inhibitory and bactericidal activity of the three cephalosporins used in subsequent interaction testing (MICs and MBCs, c8 ,ug/ml); the remaining -25% of strains were only moderately susceptible in vitro (MICs and MBCs, 16 to 64 ,ug/ml). However, this bimodal distribution of MICs and MBCs had no discernable effect on the frequency of enhanced bactericidal activities among the various drug combinations. (ii) Overall, five of the six P-lactamaminoglycoside combinations used in this study exerted an enhanced bactericidal effect against the 40 study strains at a frequency of 85 to 90%; this occurred within readily achievable drug levels in serum for all of the single antibiotic constituents. Also, in 35% of the 40 strains, all six drug combinations tested exhibited such enhanced killing. The gentamicin-ceftazidime regimen was relatively inferior to the other five drug combinations, exhibiting enhanced killing in only 60% of testings. Statistical analysis delineated that the ceftazidime component was responsible for this somewhat reduced in vitro efficacy. (iii) There was no in vitro antagonism noted in any drug combination assay. (iv) In nearly one-half of the bactericidal interactions which resulted in enhanced killing at 24 h, such bactericidal effects were also clearly demonstrable by 4 h of incubation. This finding delineated that the ,B-lactam-aminoglycoside combinations studied resulted in not only a high frequency of enhanced killing but also a rapid bactericidal interaction. This observation is somewhat different from the report of Hallander et al. in which it was seldom possible to discern enhanced killing after 4 to 6 h, even in runs with clear evidence of such interactions at 24 h (7). These disparate findings may relate to the drug levels chosen for interaction testing; we usually tested each constituent agent alone or in combination at its previously determined MBC, whereas Hallander et al. gen-VOL. 25, 1984 it-le P erally used each constituent agent at a concentration less than or equal to one-fourth its MBC (7) .
These in vitro interaction data do not establish the superiority of combinations of newer P-lactams and aminoglycosides in the therapy of serious Enterobacteriaceae infections. They do, however, suggest the need for in vivo studies to compare the efficacy of these drug combination regimens with those featuring currently available P-lactam agents.
Such in vivo studies should be performed in appropriate experimental animal model systems in which bactericidal antibiotics are important for cure (e.g., neonatal meningitis or endocarditis [5; K. S. Kim, M. Manacchio, and A. S. Bayer, Chemotherapy, in press) and in carefully conducted comparative human trials.
